What lab test is important for evaluating coagulation status pre-thrombolysis?

Evaluating coagulation status prior to thrombolysis is crucial, as the use of thrombolytic agents in patients with acute ischemic stroke can lead to serious complications, including hemorrhagic transformation if the coagulation parameters are not within acceptable limits. The International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) are the primary tests used to assess coagulation status.

INR is particularly significant for patients on anticoagulant therapy, such as warfarin, as it helps determine the risk of bleeding. aPTT evaluates the intrinsic and common pathways of coagulation and is important in assessing the efficacy of heparin therapy. Together, these tests provide comprehensive insight into whether a patient can safely receive thrombolytic therapy without significantly increasing their risk of bleeding during or after the procedure.

The remaining options do not specifically measure coagulation status. A complete blood count primarily assesses overall hematological health but does not provide direct information on coagulation factors. Liver function tests evaluate the liver's ability to produce proteins necessary for clotting but do not directly measure coagulation. C-reactive protein is an inflammatory marker and does not have any role in assessing coagulation status. Thus, INR and aPT